bpc-157 modulates neurotransmitters Stable Gastric Pentadecapeptide BPC 157 as a Therapy and Safety Key: A Special Beneficial Pleiotropic Effect Controlling and Modulating Angiogenesis and the NO-System Multifunctionality and Possible Medical Application

Phase I Safety Trial: As noted, a Phase I trial (the first step in testing a drug in humans, usually focused on safety and pharmacokinetics) was registered in 2015, aiming to give BPC-157 to healthy volunteers

Telei and Griffin, 2006)

The concern is prolonged high-dose supplementation without medical advice, or a blood test showing persistently high B12 when someone is not taking supplements

Or better yet, consider the reconstitution math before purchasing

Relamorelin, an injectable ghrelin receptor agonist, showed efficacy in diabetic gastroparesis patients with active vomiting symptoms in two placebo-controlled phase 2 studies and is being evaluated in phase 3 studies (54, 55)